Skip to main content
. 2022 Jan 7;11:786120. doi: 10.3389/fonc.2021.786120

Figure 1.

Figure 1

Study design of the phase Ib trial of citarinostat plus paclitaxel in patients with advanced solid tumors. a28-day cycles with citarinostat administered orally once daily on days 1 to 21 at all doses and paclitaxel administered intravenously on days 1, 8, and 15. bAn additional 360-mg cohort was allowed if the maximum tolerated dose was not reached.